Cardax Company Description

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress.

It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity.

The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration.

Cardax, Inc. is based in Honolulu, Hawaii.

Cardax, Inc.

Country	United States
Industry	Biotechnology
Sector	Healthcare
Employees	11
CEO	David Watumull

Contact Details

Address: 2800 Woodlawn Drive Honolulu, Delaware 96822 United States
Phone	808 457 1400
Website	cardaxpharma.com

Stock Details

Ticker Symbol	CDXI
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US14141D2018
SIC Code	2834

Key Executives

Name	Position
David G. Watumull	Chairman and Chief Executive Officer
David M. Watumull	Chief Operating Officer and Chief Financial Officer
Gilbert Shin	Vice President of Retail Sales and Marketing